Systemic Inflammation May Induce Cardiac Injury in COVID-19 Patients Including Children and Adolescents Without Underlying Cardiovascular Diseases: A Systematic Review

Abstract

Coronavirus disease 2019(COVID-19) is an ongoing global pandemic with a daily increasing number of affected individuals and a relatively high mortality rate. COVID-19 patients that develop cardiac injury are at increased risk of a worse clinical course with higher rates of mortality. Increasing amounts of evidence suggest that a system-wide inflammatory response and a cytokine storm mediated type syndrome plays a crucial role in disease progression. This systematic review investigates the possible role of hyperinflammation in inducing cardiac injury as one of the severe complications of COVID-19. A systematic literature search was performed using PubMed, Embase and Scopus databases to identify relevant clinical studies that investigatedc ardiovascular injury manifestations and reported inflammatory and cardiac biomarkers in COVID-19 patients. Only 29 studies met our inclusion criteria and the majority of these studies demonstrated significantly elevated inflammatory and cardiac blood markers. It was evident that underlying cardiovascular diseases may increase the risk of developing cardiac injury. However, many COVID-19 patients included in this review, developed different types of cardiac injury without having any underlying cardiovascular diseases. Furthermore, many of these patients were either children or adolescents. Therefore, age and comorbidities may not always be the two main risk factors that dictate the severity and outcome of COVID-19. Further investigations are required to understand the underlying mechanisms of pathogenicity as an urgent requirement to develop the appropriate treatment and prevention strategies. These strategies may specifically target hyperinflammation as a suspected driving factor forsome of the severe complications of COVID-19.

Cardiovascular and haematological events post COVID‐19 vaccination: A systematic review

“… 112 The interaction between COVID‐19 infection itself and the RAAS has been explored in depth in some of our previous studies, and the role of ACE2 in the inflammatory response remains one of the leading hypotheses explaining some of the phenomena observed with COVID‐19 infection and possibly now with vaccination as well. 113 , 114 …”

“…COVID‐19–induced CI has been well‐established. 114 Ammirati et al, 6 therefore, suggested that molecular mimicry between the SARS‐CoV‐2 viral proteins and cardiac molecules may partially explain the high incidence of CI observed during COVID‐19. Furthermore, an immuneresponse against the viral spike glycoprotein could pose a risk for immune‐mediated organ injury.…”

“…In addition to the rarity of such events, it is important to understand that COVID‐19 itself may cause CI and thrombosis. 114 , 138 Furthermore, the rate of such severe events is much higher when associated with COVID‐19 than the rate of vaccine‐induced CI and thrombosis. For example, it was reported by Shi et al 139 that 19.7% of 416 hospitalized patients with COVID‐19 had CI while a meta‐analysis by Li et al 140 reported that at least 8.0% of the COVID‐19 patients experienced acute myocardial injury.…”

Comorbidity in young patients with juvenile systemic lupus erythematosus: how can we improve management?

“…There are similarities between various processes involved in ageing and their related comorbidities and emerging research suggests that they could be targeted simultaneously for health benefits [12]. In addition, the recognised link between chronic inflammation and comorbidity, irrespective of age or underlying condition [13][14][15], can offer hope that targeted disease management from a younger age can address the life-long comorbidity risk.…”

A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle

“…They include dry cough, fever, shortness of breath, sore throat, fatigue, nasal congestion, myalgia, chills, dizziness, and in some, loss of smell and taste [ 3 ]. The severity of these manifestations varies between individuals – in particular, the worsening prognosis was associated with an increase in age and/or the presence of underlying chronic or immunodeficiency disorders [ 4 ]. Despite the accelerated development and mass roll-out of multiple COVID-19 vaccines leading to the administration of over 9 billion doses worldwide, in addition to their widely reported possible resultant adverse effects, there continues to be a lack of approved and effective therapeutic drugs as treatment or cure [ [5] , [6] , [7] ].…”